SCHEMBL4673973

SCHEMBL4673973

O=C(O)C(O)=CC(=O)c1cc(Cc2ccncc2)c[nH]1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK7 Q13164 5/20 0.38
F2 P00734 1/20 0.37
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CCNC P24863 3/20 0.36
CDK8 P49336 3/20 0.36
CYP17A1 P05093 4/20 0.35
TSHR P16473 1/20 0.35
CYP11B1 P15538 3/20 0.35
CYP11B2 P19099 3/20 0.35
CYP3A4 P08684 2/20 0.35
CYP19A1 P11511 2/20 0.35
MAPK14 Q16539 3/20 0.34
DAO P14920 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673970 1.00 MAPK7 (0.38) MAPK7F2LMNAALDH1A1HDAC1
SCHEMBL4675566 0.87 GAA (0.39) LMNAALDH1A1DAOGABRA1GABRB2
SCHEMBL4675568 0.87 GAA (0.39) LMNAALDH1A1DAOGABRA1GABRB2
SCHEMBL4675875 0.84 DAO (0.37) LMNAALDH1A1DAO
SCHEMBL4670509 0.84 ALDH1A1 (0.38) ALDH1A1CYP17A1TSHRCYP11B1CYP11B2
SCHEMBL4675216 0.84 SRD5A2 (0.40) LMNAALDH1A1DAO
SCHEMBL4670512 0.84 ALDH1A1 (0.38) ALDH1A1CYP17A1TSHRCYP11B1CYP11B2
SCHEMBL4675878 0.84 DAO (0.37) LMNAALDH1A1DAO
SCHEMBL4675213 0.84 SRD5A2 (0.40) LMNAALDH1A1DAO
SCHEMBL4674577 0.82 KMT2A (0.49) LMNAALDH1A1TSHRDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 MAPK7 3943/4885F2 3416/4885LMNA 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.